Liu Hui, Li Zhongwu, Wang Yan, Feng Qin, Si Lu, Cui Chuanliang, Guo Jun, Xue Weicheng
Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Pathology, Peking University Cancer Hospital & Institute, Beijing, China.
Pathol Int. 2014 Dec;64(12):601-6. doi: 10.1111/pin.12215. Epub 2014 Oct 31.
A novel mutation-specific monoclonal antibody VE1 was generated to detect BRAF V600E mutation with immunohistochemistry. This study aims to investigate the sensitivity and specificity of immunohistochemistry compared with conventional Sanger sequencing and to evaluate whether IHC would become the routine screening method of BRAF V600E mutation. A total of 84 cases of melanoma lesion specimens were selected to make the tissue microarray and to perform IHC with VE1 antibody. Simultaneously Sanger sequencing was applied to test and verify. VE1 has a high specificity (100%) and sensitivity (72.2%), and the concordance between the two techniques is excellent (93.8% cases coherent and kappa = 0.801). As a rapid, cost-effective method, IHC may become the routine diagnostic means for the detection of BRAF V600E mutation of malignant melanomas in the near future, and the recommended detection process is initial immunohistochemical staining for positive cases, followed by molecular techniques for negative or ambiguous cases.
生成了一种新型的突变特异性单克隆抗体VE1，用于通过免疫组织化学检测BRAF V600E突变。本研究旨在探讨免疫组织化学与传统桑格测序相比的敏感性和特异性，并评估免疫组织化学是否会成为BRAF V600E突变的常规筛查方法。共选取84例黑色素瘤病变标本制作组织芯片，并用VE1抗体进行免疫组织化学检测。同时应用桑格测序进行检测和验证。VE1具有高特异性（100%）和敏感性（72.2%），两种技术之间的一致性极佳（93.8%的病例一致，kappa = 0.801）。作为一种快速、经济有效的方法，免疫组织化学可能在不久的将来成为检测恶性黑色素瘤BRAF V600E突变的常规诊断手段，推荐的检测流程是对阳性病例进行初步免疫组织化学染色，对阴性或不明确病例采用分子技术。
